A Randomized Trial of Sibutramine in the Management of Obese Type 2 Diabetic patients Treated With Metformin

McNulty, Steven J.; Ur, Ehud; Williams, Gareth
January 2003
Diabetes Care;Jan2003, Vol. 26 Issue 1, p125
Academic Journal
OBJECTIVE To evaluate the effects of sibutramine (15 and 20 mg/day) on weight, metabolic control, and blood pressure in metformin-treated obese subjects with type 2 diabetes. RESEARCH DESIGN AND METHODS — A 12-month randomized prospective placebo-controlled double-blind study was performed. It included 21 primary and secondary care centers in England, Canada, France, and Belgium. A total of 195 subjects (44% male) with type 2 diabetes and a BMI >27 kg/m² were studied. Changes were assessed in weight, blood pressure and resting heart rate, HbA[sub 1c], fasting glucose, and lipids. RESULTS — Sibutramine inducedsignificant weight loss (P < 0.001) with both 15 mg/day (5.5 ± 0.6 kg at 12 months) and 20 mg/day (8.0 ± 0.9 kg), whereas placebo did not (0.2 ± 0.5 kg). Weight loss ≥10% was achieved by 14 and 27% of subjects receiving 15 and 20 mg, respectively, but by none given placebo. Glycemic control improved in parallel with weight loss, and subjects who lost ≥10% weight showed significant decreases m both HbA[sub 1c] (1.2 ± 0.4%, P < 0.0001) and fasting plasma glucose (1.8 mmol/1, P < 0.001). HDL cholesterol increased slightly with the higher dose, whereas plasma triglycerides fell with both doses, especially in subjects with weight loss of ≥ 10% (a 29% decrease, P < 0.01). Treatment was generally well tolerated. Sibutramine treatment raised sitting diastolic blood pressure by ≥5 mmHg in a higher proportion of patients than did placebo (43% with 15 mg/day vs. 25% with placebo, P < 0.05), but this effect was less evident in subjects who had a weight loss of ≥10% weight. Pulse rate increased significantly more with sibutramine, being ≥ 10 bpm higher in 42 % of treated patients versus 17% with placebo (P < 0.01). CONCLUSIONS — Sibutramine can be an effective adjunct to metformin treatment in selected obese type 2 diabetic subjects and improves metabolic control in individuals who lose weight.


Related Articles

  • Cardiovascular Effects of Pharmacologic Treatments for Obesity. Aronne, Louis J. // Nutrition in Clinical Care;Jan/Feb98 Supplement 1, Vol. 1 Issue 1, p51 

    Examines the cardiovascular effects of pharmacologic treatment for obesity in the United States. Complications of obesity; Development of sibutramine as an antidepressant; Association between sibutramine and heart disease and hypertension.

  • Continuous and intermittent sibutramine were equally effective at 44 weeks for reducing weight in obese persons. Cheskin, Lawrence J. // ACP Journal Club;Mar/Apr2002, Vol. 136 Issue 2, p49 

    Presents information on a study which examined the effectiveness of sibutramine for reducing weight in obese patients. Methodology of the study; Results; Comments on the study.

  • Sibutramine safety review.  // WHO Drug Information;2002, Vol. 16 Issue 1, p26 

    Reports on action taken by regulatory agencies of various countries regarding the prescription drug sibutramine. Approval of the drug in Canada in December 2000 to treat obesity; Italian authorities' temporary suspension of market authorization of all drugs containing sibutramine in March 2002;...

  • Pharmacological Treatment of Obesity: Current Standards and Future Perspectives. Romijn, J. A.; Smit, J. W. A.; Pereira, A. M.; Corssmit, E. P. M.; Pijl, H. // Immunology, Endocrine & Metabolic Agents - Medicinal Chemistry;Feb2006, Vol. 6 Issue 1, p119 

    The long-term effects on weight have only been studied for orlistat and sibutramine. The net effects of these drugs vary between 2-5% loss of weight after 1-2 years of treatment. However, the effects of orlistat and sibutramine on morbidity and mortality have not been studied extensively. In the...

  • FROM THE ANALYST'S COUCH: Obesity market overview. Farrigan, Christine; Pang, Kevin // Nature Reviews Drug Discovery;Apr2002, Vol. 1 Issue 4, p257 

    Presents an overview of available pharmacological therapies for obesity. Sibutramine; Axokine; Bupropion; Recombinant human leptin; Topiramate; Forecast of sales of antiobesity agents by 2010.

  • A clinical trial of the use of Sibutramine for the treatment of patients suffering essential obesity. Fanghänel, G; Cortinas, L; Sánchez-Reyes, L; Berber, A // International Journal of Obesity & Related Metabolic Disorders;Feb2000, Vol. 24 Issue 2, p144 

    OBJECTIVE: To evaluate the safety and efficacy of Sibutramine 10 mg per os, once a day in obese patients over a period of 6 months. DESIGN: A monocenter, double-blind, placebo-controlled, parallel, prospective clinical trial. SUBJECTS: 109 male and female obese patients (BMI >30 kg/m²) from...

  • Sibutramine/zolpidem interaction.  // Reactions Weekly;Feb2014, Vol. 1488 Issue 1, p31 

    The article presents a case study of a 61-year old woman who suffered from two psychotic episodes during treatment with sibutramine for obesity.

  • BATTLING THE BULGE. Beyzarov, Elena Portyansky // Drug Topics;8/21/2000, Vol. 144 Issue 16, p51 

    Deals with the drugs and herbal medicines to fight obesity. Factors causing obesity and its health implications; Evaluation of earlier pharmacologic treatments for obesity; Mechanism of action and side effects of Meridia and Xenical drugs; Herbal ingredients in weight loss supplements. INSET:...

  • New Trends in Medicinal Chemistry Approaches to Antiobesity Therapy. Jinhwa Lee; Kwang-Seop Song; Jahyo Kang; Suk Ho Lee; Junwon Lee // Current Topics in Medicinal Chemistry;Apr2009, Vol. 9 Issue 6, p564 

    The prevalences of overweightedness and obesity are increasing globally at frightening rates, driven by social and economic changes. Furthermore, obesity is associated with the pathogeneses of major diseases, particularly diabetes and cardiovascular diseases. However, no satisfactorily safe,...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics